China will soon begin clinical trials with the drug for Covid-19 developed by the state-run pharmaceutical CNBG, based on the plasma of recovered patients and considered by the state press to be the first of its kind in the world.
“Animal test results show that it can considerably relieve the symptoms and damage caused by the coronavirus. It has just received approval from the State Drug Administration and clinical research will soon begin, ”CNBG Vice President Zhu Jingjin assured.
Through a message posted this Sunday on the Chinese social network’s WeChat account of the State Council’s Property Administration and Supervision Commission, Zhu detailed that “Plasma from patients recovered from covid (…) gives good results with critical and severe patients” from covid-19.
According to the source, this type of treatment elicits a faster response for this type of at-risk patients.
However, Jiang Chulai, of Jilin University, clarified that “the actual effectiveness of a special drug still depends mainly on the results of clinical trials, rather than on the conclusions of the early stages.”
Another source also cited by the state newspaper Global Times has postulated that medications serve to alleviate the effects of infection, but that prevention and vaccination remain the most effective ways to curb infections and their effects.
CNBG and its parent company, the state Sinopharm, Have so far developed two vaccines for the inactivated Covid-19 virus that are being used in countries such as Brazil, Indonesia, the United Arab Emirates or China itself.
The latest data from the National Health Commission of China show that the Asian country has inoculated more than 2.1 billion doses of covid vaccines, Much of them, those developed by CNBG and Sinopharm
The company has also indicated that it is working on two vaccines for the covid of different technologies (one of them, messenger RNA, such as those of the American pharmaceutical companies Pfizer and Moderna) which, according to Zhu, are currently have been shown to be effective against new strains of the SARs-CoV-2 coronavirus.